{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 3,
  "pageCount": 29,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a list of callout boxes to highlight key company milestones and financial status.",
  "elementsJson": [
    "headline_text",
    "callout_box"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/3",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-3",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "DURAVYU™: vorolanib - best-in-class, patent protected TKI in Durasert E™ sustained delivery technology",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a61e-a7cdfb58e811",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.012,
        "w": 0.504,
        "x": 0.348,
        "y": 0.942
      },
      "kind": "disclaimer",
      "text": "TKI tyrosine kinase inhibitor; wet AMD, wet age-related macular degeneration; DME, diabetic macular edema",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3a26fe55-9c27-460b-a865-4cfff3790fd7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.634,
        "x": 0.183,
        "y": 0.661
      },
      "kind": "list",
      "text": "Favorable safety profile across multiple indications in 190+ patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e093a16-7081-4e82-9441-dfa79070e338",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.634,
        "x": 0.183,
        "y": 0.521
      },
      "kind": "list",
      "text": "Highly positive efficacy and safety data in DME from VERONA Phase 2 trial",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f8fd995-b3a9-4c98-ae04-8bf3f5367a0a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.634,
        "x": 0.183,
        "y": 0.381
      },
      "kind": "list",
      "text": "Pivotal Phase 3 trial in wet AMD, LUGANO fully enrolled; LUCIA 60% enrolled and randomized",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af66b7b3-dd46-4d48-a5b3-9fc0a1623cd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.634,
        "x": 0.183,
        "y": 0.801
      },
      "kind": "list",
      "text": "$318M at 3/31/25 – runway into 2027 post Phase 3 LUGANO/LUCIA data in 2026",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccc5b500-d305-4db7-8e04-0d8343a89128",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.075,
        "w": 0.634,
        "x": 0.183,
        "y": 0.241
      },
      "kind": "list",
      "text": "DURAVYU™: vorolanib - best-in-class, patent protected TKI in Durasert E™ sustained delivery technology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff594e7f-9457-4b32-84d3-eb0c6eb12958",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Cash runway: $318M",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a61e-a85974dcae8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "The Leader in Sustained Release Drug Delivery for Retinal Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "104309d4-d679-4f19-9482-dee7d28236b2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "aa6d1ed3-30f1-42fd-aa68-e7c0bfea7c8b",
      "evidence": "This slide is titled 'The Leader in Sustained Release Drug Delivery for Retinal Disease' and contains a summary of key points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}